These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 19574101)

  • 1. Anti-inflammatory drugs, antioxidants, and prostate cancer prevention.
    Bardia A; Platz EA; Yegnasubramanian S; De Marzo AM; Nelson WG
    Curr Opin Pharmacol; 2009 Aug; 9(4):419-26. PubMed ID: 19574101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agents in development for prostate cancer prevention.
    Nelson WG
    Expert Opin Investig Drugs; 2004 Dec; 13(12):1541-54. PubMed ID: 15566312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preneoplastic prostate lesions: an opportunity for prostate cancer prevention.
    Nelson WG; De Marzo AM; Deweese TL; Lin X; Brooks JD; Putzi MJ; Nelson CP; Groopman JD; Kensler TW
    Ann N Y Acad Sci; 2001 Dec; 952():135-44. PubMed ID: 11795433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antioxidants for prostate cancer chemoprevention: challenges and opportunities.
    Thapa D; Ghosh R
    Biochem Pharmacol; 2012 May; 83(10):1319-30. PubMed ID: 22248733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progress in prostate cancer chemoprevention: modulators of promotion and progression.
    Lieberman R; Bermejo C; Akaza H; Greenwald P; Fair W; Thompson I
    Urology; 2001 Dec; 58(6):835-42. PubMed ID: 11744441
    [No Abstract]   [Full Text] [Related]  

  • 6. High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research.
    Marshall JR
    IARC Sci Publ; 2001; 154():191-8. PubMed ID: 11220658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents.
    Nelson WG; Wilding G
    Urology; 2001 Apr; 57(4 Suppl 1):56-63. PubMed ID: 11295596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent role of inflammation in prostate diseases: chemoprevention development opportunity.
    Hamid AR; Umbas R; Mochtar CA
    Acta Med Indones; 2011 Jan; 43(1):59-65. PubMed ID: 21339547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoprevention of prostate cancer by diet-derived antioxidant agents and hormonal manipulation (Review).
    Pathak SK; Sharma RA; Mellon JK
    Int J Oncol; 2003 Jan; 22(1):5-13. PubMed ID: 12469179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of prostate cancer: agents and study designs.
    Thompson IM
    J Urol; 2007 Sep; 178(3 Pt 2):S9-S13. PubMed ID: 17644117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of inflammation in the pathogenesis of prostate cancer.
    Nelson WG; De Marzo AM; DeWeese TL; Isaacs WB
    J Urol; 2004 Nov; 172(5 Pt 2):S6-11; discussion S11-2. PubMed ID: 15535435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention in prostate cancer.
    Assikis V; Brawley OW
    Curr Probl Cancer; 2004; 28(4):218-30. PubMed ID: 15318324
    [No Abstract]   [Full Text] [Related]  

  • 14. Chemoprevention of prostate cancer: current status and future directions.
    Lieberman R
    Cancer Metastasis Rev; 2002; 21(3-4):297-309. PubMed ID: 12549768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we prevent prostate cancer? Rationale and current status of prostate cancer chemoprevention.
    Fujimoto N; Chang C; Nomura M; Matsumoto T
    Urol Int; 2005; 74(4):289-97. PubMed ID: 15897691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison.
    Cui K; Li X; Du Y; Tang X; Arai S; Geng Y; Xi Y; Xu H; Zhou Y; Ma W; Zhang T
    Oncotarget; 2017 May; 8(22):36674-36684. PubMed ID: 28415774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apoptotic index as a biomarker in prostatic intraepithelial neoplasia (PIN) and prostate cancer.
    Wheeler TM; Rogers E; Aihara M; Scardino PT; Thompson TC
    J Cell Biochem Suppl; 1994; 19():202-7. PubMed ID: 7823593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer chemoprevention: Strategies for designing efficient clinical trials.
    Lieberman R
    Urology; 2001 Apr; 57(4 Suppl 1):224-9. PubMed ID: 11295633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer.
    Kelloff GJ; Lieberman R; Steele VE; Boone CW; Lubet RA; Kopelovich L; Malone WA; Crowell JA; Higley HR; Sigman CC
    Urology; 2001 Apr; 57(4 Suppl 1):46-51. PubMed ID: 11295594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of inflammatory mediators in the development of prostatic hyperplasia and prostate cancer.
    Elkahwaji JE
    Res Rep Urol; 2012 Dec; 5():1-10. PubMed ID: 24400229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.